GlassScriptPhysician profile
Amy L Ward
NPI 1497303697
$16,323.13
in general payments reported to CMS, 2019-2025
23 companies · $5,149 in 2025
The $5,149 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,301 · 2023: $1,785 · 2024: $7,019 · 2025: $5,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,356 · Food and Beverage: $5,924 · Travel and Lodging: $566 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,356.00 |
| Food and Beverage | $5,924.36 |
| Travel and Lodging | $566.30 |
| Education | $106.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $9,943.37 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,361.08 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $879.56 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $798.48 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $724.00 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $630.30 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $599.01 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Ironshore Pharmaceuticals INC. | $299.65 | 2021-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $221.70 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $199.09 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $149.31 | 2023-2024 | Auvelity |
| Lundbeck LLC | $121.41 | 2021-2025 | Rexulti |
| Corium, LLC | $85.10 | 2023-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $75.93 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.80 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $27.82 | 2022 | |
| Almatica Pharma LLC | $26.84 | 2022 | |
| Adlon Therapeutics L.P. | $24.89 | 2021 | |
| Vertical Pharmaceuticals, LLC | $22.14 | 2024 | Relexxii |
| Renalytix Ai, INC. | $22.14 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Neuronetics, INC. | $20.92 | 2023 | Neurostar Tms Therapy System |
| Indivior INC. | $20.05 | 2023 | Perseris |
| Tris Pharma INC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.